Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-02-01
2005-02-01
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S058200
Reexamination Certificate
active
06849624
ABSTRACT:
The invention is the compounds2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-N-methyl-isobutyramide and2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methyl-isobutyramide.Compounds of the invention are useful in pharmaceutical compositions for the treatment of migraine, rheumatoid arthritis, asthma, bronchial hyperreactivity, inflammatory bowel disease or for the treatment of disorders including Parkinson's disease, anxiety, depression, pain, headache, Alzheimer's disease, multiple sclerosis, edema, allergic rhinitis, Crohn's disease, ocular injury, ocular inflammatory diseases, psychosis, motion sickness, induced vomiting, emesis, urinary incontinence, psychoimmunologic or psychosomatic disorders, cancer, withdrawal symptoms of addictive drugs from opiates or nicotine, traumatic brain injury or benign prostatic hyperplasia.
REFERENCES:
patent: 5972938 (1999-10-01), Rupniak et al.
patent: 20030004157 (2003-01-01), Buser et al.
patent: 1 035 115 (2000-09-01), None
patent: 2 347 422 (2000-09-01), None
patent: WO 9516679 (1995-06-01), None
patent: WO 9518124 (1995-07-01), None
patent: WO 9523798 (1995-09-01), None
patent: WO 02 085458 (2002-10-01), None
Stout et al, “Neurokinin 1 Receptor Antagonists as Potential Antidepressants” Annu. Rev. Pharmacol. Toxicol. vol. 41, pp. 877-906 (2001).*
Rupniak, N. “Elucidating the antidepressant actions of substance P (NK 1 receptor) antagonists” Current Opinion in Investigational New Drugs, vol. 3(2), pp. 157-261 (2002).*
Humphrey, J. “Medicinal Chemistry of Selective Neurokinin-1 Antagonists” Current Topics in Medicinal Chemistry, vol. 3, p. 1423-1435 (2003).*
Navari, et al.,New England J. of Medicine, vol. 340,pp. 190-195 (1999).
Maggi et al.,J. Auton. Pharmacol., vol. 13, pp. 23-93 (1993).
Kramer et al.,Science, vol. 281, pp. 1640-1645 (1998).
Longmore et al.,Can. J. Physiol. Pharmacol., vol. 75, pp. 612-621 (1997).
Barker,Reviews in Neurosciences, vol. 7, pp. 187-214 (1996).
Maggi et al.,Neuropeptides., vol. 32(1), pp. 1-49 (1998).
Doi et al.,Eur. J. of Pharmacology., vol. 383(3), pp. 297-303 (1999).
Palma et al.,Life Sciences., vol. 67(9), pp. 985-1001 (2000).
Mutra et al.,Nature., vol. 405, pp. 180-183 (2000).
Ballard Theresa Maria
Hoffmann Torsten
Poli Sonia Maria
Schnider Patrick
Sleight Andrew
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Raymond Richard L.
Rocha-Tramaloni Patricia S.
LandOfFree
Aromatic and heteroaromatic substituted amides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aromatic and heteroaromatic substituted amides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aromatic and heteroaromatic substituted amides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3460679